Dr. Gitelman's research interests include type 1 and type 2 diabetes, especially issues related to children and adolescents. On-going research studies include:

• Prevention of type 1 diabetes mellitus, including: a) participation in NIH-sponsored studies such as TrialNet to better understand the natural history and prevent type 1 diabetes, and b) the use of novel immunomodulatory agents at diagnosis to prolong endogenous insulin secretion (the honeymoon phase), such as with a humanized anti-CD3 monoclonal antibody and anti-thymocyte globulin.
• Use of insulin pump therapy, continuous glucose sensors, and other evolving technologies to optimize metabolic control for children with diabetes
• Improving outcomes for Latino youth with diabetes
• Prevention of type 2 diabetes in obese adolescents
• Post-transplantation diabetes in children

Selected Publications:

2005 Diabetes Prevention Trial – Type 1 Study Group[Gitelman SE—Study Group Member]. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 28: 1068-1076.

2005 Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352: 1884-1890.

2005 Herold KC, Bisikirska B, Gitelman SE, Masharani U, Hagopian W, Donaldson D, Rother K, Diamond B, Harlan D, Bluestone JA. A single course of anti-CD3 mAbhOKT3γ1(Ala-Ala) results in improvement in insulin secretion and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 54: 1763-9.

2005 Huang E, Feldman B, Geller D, Schwartz D, Gitelman SE. Urea for treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatrics, in press.2005 Sapru A, Gitelman SE, Bhatia S, Dubin R, Flori H. Prevalence and Characteristics of Type 2 Diabetes Mellitus in 9-18 year old children with Diabetic Ketoacidosis. J Pediatric Endocrinol Metab, In press.

2005 Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two center randomized controlled trial of insulin pump therapy in young children with diabetes. Diabetes Care 28: 15-19.

2004 Steele C., Hagopian, WA, Gitelman SE, Masharani U, Cavaghan M, Rother K, Donaldson, D, Harlan D, Bluestone J, Herold KC. Insulin secretion in type 1 diabetes. Diabetes 53: 426-33.

2004 Conrad SC, Mastratatoro J, Gitelman SE. Use of the continuous glucose sensor for evaluation of hypoglycemia. J Pediatric Endocrinol Metab 17: 281-88.

2002 Greenspan LC, Gitelman SE, Mathias R. Increasing incidence of diabetes mellitus at a large pediatric renal transplant center. Pediatric Nephrology, 17:1-5.

2002 Conrad SC, McGrath MT, Gitelman SE. Transition from multiple daily injections (MDI) to continuous subcutaneous insulin infusion (CSII): characteristics of a pediatric population. J Pediatrics,140: 235-40.

2002 Herold KC, Hagopian W, Auger J, Poumain-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan D, Xu D, Zivin R, Bluestone JA. Effects of anti-CD3 mAb hOKT31(Ala-Ala) in patients with new onset Type 1 diabetes mellitus. N Engl J Med, 346: 1692-1698.

2002 Diabetes Prevention Trial – Type 1 Study Group[Gitelman SE—Study Group Member]. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med, 346: 1685-1691b.